4th Controlled Human Infection Model (CHIM) Meeting
May 22-25, 2023
Informations will be available soon
Maintening the Quality of Vaccines through the Use of References Standards Current Challenges and Future Opportunities
June 21 – June 22, 2023
President’s Column 2022
Dear IABS Colleagues, Stakeholders, Supporters, and Collaborators,
It was an honor to assume the presidency of this prestigious organization in 2022. IABS has a celebrated history, and I am looking forward to more accomplishments…
What does IABS do that is unique ?
In this short interview, Joris Vandeputte, former President of IABS has answered the question “What does IABS do that is unique ?”
To learn more about the International Alliance for Biological…
INNOVATIVE MEDICINES INITIATIVE (IMI) PROJECTS :
IMI is a European public-private partnership aiming to speed up the development of better and safer medicines. IMI is partly founded by the European Commission.
The IABS European Affiliate (IABS-EU) was part of consortia which have been selected by IMI to be the public partners of following consortia.
IABS-EU was selected to drive the regulatory part of those consortia.
IABS COLLABORATIONS / MANCO, A EUROPEAN COMMISSION PROJECT :
MANCO (Monclonal Antibodies against COVID-19) is one of the eighteen projects that have been successfully selected by the European Commission, which is devoted to the development of Monoclonal Antibodies agains COVID-19.
IABES-EU was selected to drive the regulatory part of the project